English
banner
Products
Home

Prostaglandin Series

TRAVOPROST 157283-68-6

TRAVOPROST 157283-68-6

99% up, USP32
  • Product Details

Product Information


Product name

Travoprost

Molecular Formula

C26H35F3O6

Molecular Weight

500.55

CAS No.

157283-68-6

Quality Standard

96% up, USP32

Appearance

Colorless oil


COA of Travoporst


Tests

Specifications

Results

Description

A pale yellow to colorless oil

A colorless oil

Identification

TLC; HPLC

Complies

Specific Rotation

+52°~+58°

+53.15°

Water

1.0%

0.30%

Related compunds

Epoxide derivative 1)0.4%

Not detectable

15-epi Diastereomer 2)0.1%

0.03%

5,6-trans Isomer 3)3.5%

0.26%

15-Keto derivative 4)0.3%

0.06%

Any other impurity 0.1%

0.03%

Total other impurities 1.0%

0.06%

Residue Solvent

Isopropanol0.5%

Not detectable

Ethyl acetate0.25%

Not detectable

N-Hexane 0.029%

Not detectable

Ethanol0.5%

0.33%

Purity by HPLC

96.0%~102%

99.59%


Usage


Function of Travoprost
Glaucoma is a serious eye disease that threatens human health. It is a blinding eye disease that seriously threatens human visual function. It is the second most blind factor in the world. Its main features are increased intraocular pressure, optic nerve damage, decreased vision and visual field. Shrinkage, severe cases and even vision loss. At present, there is no direct treatment for glaucoma optic neuropathy. The main treatment is to control intraocular pressure and prevent further damage to the optic nerve function. Glaucoma local ocular pressure-lowering drugs have been focusing on the study of inhibiting the production of ciliary body aqueous humor and promoting the outflow of trabecular meshwork water. The drugs for treating glaucoma are mainly eye drops, including β-blockers and pseudo-sympathetic drugs. , Carbonic anhydrase inhibitors, α-receptor agonists, and prostaglandin (PG) analogs. PGs are a class of unsaturated 20-carbon Chemicalbook fatty acids derived from arachidonic acid. PGs, especially PGF2α, are currently considered to be the most promising and effective ocular local pressure reducing drugs. PG analogues such as PGF2α reduce the intraocular pressure by activating PGFP receptors. The combination of these drugs and the PGFP receptor initiates a series of biochemical reactions, opening the uveal sclera drainage pathway, increasing the outflow of aqueous humor, and thereby reducing intraocular pressure. PG analogs, especially PGFP receptor agonists, are a class of approved and effective new drugs for lowering intraocular pressure. Due to the good effect of lowering intraocular pressure, fewer adverse reactions, and fewer times of medication, they have become the main clinical eye drop Press drugs.

Travoprost is a new type of PG drugs, is an analogue of PGF2α, has a high selectivity and affinity for PGFP receptors, is a complete agonist, is by the US Food and Drug Administration (FDA) A PG drug approved in September 2006 for the treatment of primary open-angle glaucoma and ocular hypertension. The molecular structure of travoprost contains a pentene ring with α- and ω-carbon chains. The esters at the end of the α-chain help penetrate the cornea and decompose into free acids in the stroma of the cornea. FP receptors combine to reduce intraocular pressure by increasing the outflow of aqueous humor through the uveal scleral pathway.

Send A Message

If you are interested in our products and want to know more details,please leave a message here,we will reply you as soon as we can.
Related Products

Send A Message
Send A Message
If you are interested in our products and want to know more details,please leave a message here,we will reply you as soon as we can.

Home

Products

about

Contact